Bogota Colombia
A Massachusetts-based biotechnology company has been testing a possible vaccine against the new coronavirus that shows early signs of success.
Moderna Therapeutics announced an estimated start date for the Phase 3 trials, their final trial phase.
The trial involved 45 volunteers aged 18 to 55 years who received one of three vaccine dosage levels, which were administered in two injections one month apart.
The researchers measured the antibodies that recognize the virus in all participants and detected levels similar or higher than those found in the blood of people who recovered from COVID-19.
It is unclear how long the immune response will protect against COVID-19, but volunteers will be monitored for a year to find out. Some participants experienced mild side effects, such as fatigue, chills, headache, and weakness.
The Moderna vaccine, which is being developed in conjunction with the U.S. National Institute of Allergy and Infectious Diseases (NIAID), began human safety testing in March. Phase 3 testing will begin on July 27 and will involve 30,000 people, according to a press release from May 18.
Half of the participants will be a control group that will receive placebos. This large clinical trial is expected to be completed in late October.
More than 100 vaccines are being studied worldwide for use against COVID-19, and at least eight of them have already progressed to human studies.
The Anadolu Agency website contains only part of the news that is offered to subscribers in the AA News Transmission System (HAS), and in summary form. Please contact us for subscription options.
.
